Key Takeaways
Extended Takeaways
- In this 28-day inpatient trial, iloperidone was started with a 4-day titration to 24 mg/d (12 mg twice daily), or 12 mg/d in CYP2D6 poor metabolizers, which is relevant when planning acute treatment and managing QTc risk.
- Antimanic benefit separated from placebo by day 14 and remained significant on days 21 and 28, suggesting clinicians should not expect a clear efficacy signal in the first week of treatment.
- The study supports iloperidone for mania symptom control rather than bipolar depressive symptoms, because CGI-S, CGI-C, and YMRS responder outcomes improved at day 28 while MADRS change from baseline did not reach statistical significance.
- Orthostatic effects were most prominent during titration and were placebo-like by later visits, with orthostatic response at week 4 in 5.6% of iloperidone-treated patients and 4.5% of placebo-treated patients, so blood pressure monitoring is especially important early in treatment.
- Cardiac monitoring remains clinically relevant with iloperidone: mean QTcF change from baseline to day 28 was +8.3 msec versus −1.0 msec with placebo, and post-randomization QTcF increases of ≥ 60 msec occurred in 3 iloperidone patients and 0 placebo patients.
- Weight and autonomic adverse effects may shape treatment selection in bipolar mania, as common adverse events with iloperidone included tachycardia 17.5%, dizziness 11.2%, dry mouth 9.2%, and increased weight 5.8%, with mean weight change of 4.60 ± 4.271 kg versus 1.63 ± 3.578 kg on placebo.
